The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| NERV | +81.13% | -82.48% | -29.39% | -92% |
| S&P | +13.09% | +85.73% | +13.17% | +248% |
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.
The biotech's shares are mounting a modest comeback after their ugly decline on Friday.
The company's lead drug candidate flopped in a phase 3 trial. Can a longer-term follow-up study resurrect the asset?
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.00M | 75.8% |
| Market Cap | $14.72M | -21.2% |
| Market Cap / Employee | $1.84M | 0.0% |
| Employees | 8 | -11.1% |
| Net Income | -$2.74M | -112.2% |
| EBITDA | -$2.84M | 34.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $12.39M | -53.5% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $60.00M | 0.0% |
| Short Term Debt | $0.00M | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -39.57% | -33.3% |
| Return On Invested Capital | -146.73% | 52.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2.92M | 33.0% |
| Operating Free Cash Flow | -$2.92M | 33.0% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change | |
|---|---|---|---|---|---|
| Price to Earnings | 11.69 | 2.06 | 1.16 | - | |
| Price to Book | -0.72 | -0.46 | -0.41 | -0.46 | 9.24% |
| Price to Tangible Book Value | -0.43 | -0.29 | -0.27 | -0.31 | -0.35% |
| Enterprise Value to EBITDA | -12.24 | -14.22 | -17.10 | -22.35 | 81.93% |
| Total Debt | $60.00M | $60.00M | $60.00M | $60.00M | - |
No podcast episodes available.
NERV earnings call for the period ending December 31, 2020.
NERV earnings call for the period ending September 30, 2020.
NERV earnings call for the period ending June 30, 2020.
NERV earnings call for the period ending March 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
